Trial Profile

Safety and Immunotherapeutic Activity of Cemiplimab in Participants With HBV on Suppressive Antiviral Therapy: A Phase I/II Ascending Multiple Dose Study

Status: Withdrawn prior to enrolment

Phase of Trial: Phase I/II

Latest Information Update: 11 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary)
Indications Hepatitis B
Focus Adverse reactions

Most Recent Events

08 Aug 2023 Planned initiation date changed from 30 Jun 2023 to 1 Jan 2024.
01 Aug 2023 Status changed from suspended to withdrawn prior to enrolment because the study is temporarily closed to enrollment.
05 May 2023 Planned End Date changed from 31 Mar 2024 to 30 Sep 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com